To explore the recent changes in access to GLP-1 medications and the implications of these changes on treatment sustainability, emphasizing the importance of long-term patient adherence.
Key Findings:
GLP-1 medications have become more affordable, with prices dropping below $350 per month.
High discontinuation rates within the first year of treatment indicate affordability alone may not ensure sustained use, highlighting the need for ongoing support.
The model of direct-to-consumer access is being explored for other chronic disease medications.
Interpretation:
While access to GLP-1 medications has improved, maintaining long-term treatment remains a challenge due to structural issues, limited insurance coverage, and the need for ongoing patient support.
Limitations:
Cash-pay channels do not contribute to insurance deductibles or out-of-pocket maximums.
Legal and regulatory challenges, such as patent issues and FDA restrictions, may impact the viability of telehealth platforms providing GLP-1 access.
Conclusion:
The future of this access model for chronic disease medications remains uncertain, dependent on the ability to provide continuous care beyond initial affordability and addressing the structural barriers to long-term treatment.
